Efficacy and safety of selective internal radiotherapy with yttrium-90 resin microspheres compared with sorafenib in locally advanced and inoperable hepatocellular carcinoma (SARAH): an open-label randomised controlled phase 3 trial

The Lancet Oncology

Volumn 18, Issue 12, 2017, Pages 1624-1636

  Vilgrain, Valérie ^a,b,c,r   Pereira, Helena ^d,e   Assenat, Eric ^f,r   Guiu, Boris ^f,r   Ilonca, Alina Diana ^g   Pageaux, Georges Philippe ^f,r   Sibert, Annie ^a,r   Bouattour, Mohamed ^a,r   Lebtahi, Rachida ^a,r   Allaham, Wassim ^a,r   Barraud, Hélène ^h,r   Laurent, Valérie ^h,r   Mathias, Elodie ^h,r   Bronowicki, Jean Pierre ^h,r   Tasu, Jean Pierre ^i,r   Perdrisot, Rémy ^i,r   Silvain, Christine ^i,r   Gerolami, René ^j,k,r   Mundler, Olivier ^j,r   Seitz, Jean Francois ^j,k,r   Vidal, Vincent ^j,r   Aubé, Christophe ^l,r   Oberti, Frédéric ^l,r   Couturier, Olivier ^l,r   Brenot Rossi, Isabelle ^m,r   Raoul, Jean Luc ^m,r   Sarran, Anthony ^m,r   Costentin, Charlotte ^n,r   Itti, Emmanuel ^n,r   Luciani, Alain ^n,o,p,r   Adam, René ^q,r   Lewin, Maïté ^q,r   Samuel, Didier ^q,r   Ronot, Maxime ^a,b,c,r   Dinut, Aurelia ^d,e   Castera, Laurent ^a,b,c,r   Chatellier, Gilles ^b,d,e   Delhom Christol, Elisabeth ^r   Ilonca, Alina D ^r   Lonjon, Julie ^r   Abdel Rehim, Mohamed ^r   Dieudonné, Arnaud ^r   Bazin, Christophe ^r   Chagneau Derrode, Carine ^r   Borentain, Patrick ^r   Bouvier, Antoine ^r   Vervueren, Laurent ^r   Chalaye, Julia ^r   Kobeiter, Hicham ^r   Edeline, Julien ^r   Garin, Etienne ^r   Rolland, Yan ^r   Archambeaud, Isabelle ^r   Eugene, Thomas ^r   Frampas, Eric ^r   Cassinotto, Christophe ^r   Guyot, Martine ^r   Hiriart, Jean Baptiste ^r   Lapuyade, Bruno ^r   Vergniol, Julien ^r   Bachellier, Philippe ^r   Detour, Julien ^r   Duclos, Bernard ^r   Greget, Michel ^r   Habersetzer, Francois ^r   Imperiale, Alessio ^r   Merle, Philippe ^r   Rode, Agnès ^r   Morvan, Julie ^r   Nguyen Khac, Eric ^r   Yzet, Thierry ^r   Baudin, Guillaume ^r   Chevallier, Patrick ^r   Mahamat, Abakar ^r   Piche, Thierry ^r   Razzouk, Micheline ^r   Hillon, Patrick ^r   Loffroy, Romaric ^r   Toubeau, Michel ^r   Vincent, Julie ^r   Barabino, Gabriele ^r   Bouarioua, Nadia ^r   Cuilleron, Muriel ^r   Ecochard, Marie ^r   Prevot Bitot, Nathalie ^r   Leroy, Vincent ^r   Roux, Julie ^r   Sengel, Christian ^r   Bourcier, Valérie ^r   Ganne Carrie, Nathalie ^r   Seror, Olivier ^r   Costo, Sylvie ^r   Dao, Thông ^r   Pelage, Jean Pierre ^r   Dumortier, Jérôme ^r   Giammarile, Francesco ^r   Valette, Pierre Jean ^r   Ghazzar, Nadia ^r   Pellerin, Olivier ^r   Taieb, Julien ^r   Weinmann, Pierre ^r   Heurgue Berlot, Alexandra ^r   Marcus, Claude ^r   Sommacale, Daniele ^r   Castilla Lièvre, Maria Angéla ^r   Maitre, Sophie ^r   Marthey, Lysiane ^r   more..

^a ASSISTANCE PUBLIQUE HÔPITAUX DE PARIS   (France)

^b UNIVERSITÉ PARIS DESCARTES   (France)

^c CENTRE DE RECHERCHE SUR L INFLAMMATION   (France)

^d HÔPITAL EUROPÉEN GEORGES POMPIDOU   (France)

^e INSERM   (France)

^f HÔPITAL SAINT ELOI   (France)

^g GUI DE CHAULIAC HOSPITAL   (France)

^h CHU NANCY BRABOIS   (France)

ⁱ POITIERS UNIVERSITY HOSPITAL   (France)

^j TIMONE HOSPITAL   (France)

^k AIX MARSEILLE UNIVERSITY   (France)

^l ANGERS UNIVERSITY HOSPITAL   (France)

^m INSTITUT PAOLI CALMETTES   (France)

ⁿ HENRI MONDOR HOSPITAL   (France)

^o FACULTÉ DE MÉDECINE   (France)

^p INSERM U955   (France)

^q HÔPITAL PAUL BROUSSE   (France)

^r NONE

more..

Author keywords

[No Author keywords available]

Indexed keywords

MICROSPHERE; RESIN; SORAFENIB; YTTRIUM 90; ANTINEOPLASTIC AGENT; CARBANILAMIDE DERIVATIVE; NICOTINAMIDE; YTTRIUM; YTTRIUM-90;

ABDOMINAL PAIN; ADVANCED CANCER; AGED; ALOPECIA; ANOREXIA; ARTICLE; ASCITES; BLEEDING; CANCER LOCALIZATION; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURVIVAL; CHEMOEMBOLIZATION; CHILD PUGH SCORE; CLINICAL EFFECTIVENESS; CONTINUOUS INFUSION; CONTROLLED STUDY; DIARRHEA; DRUG EFFICACY; DRUG SAFETY; DRY SKIN; FATIGUE; FEMALE; FEVER; FRANCE; GASTROINTESTINAL HEMORRHAGE; HAND FOOT SYNDROME; HEART FAILURE; HUMAN; HYPERBILIRUBINEMIA; HYPERTENSION; HYPONATREMIA; INFECTION; INTENTION TO TREAT ANALYSIS; KIDNEY FAILURE; LIFE EXPECTANCY; LIVER CELL CARCINOMA; LIVER DYSFUNCTION; LIVER TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NAUSEA; OVERALL SURVIVAL; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; PRURITUS; RANDOMIZED CONTROLLED TRIAL; RASH; SIDE EFFECT; STOMACH ULCER; SURVIVAL TIME; TUMOR INVASION; VOMITING; WEIGHT REDUCTION; ADULT; ANALOGS AND DERIVATIVES; BRACHYTHERAPY; CLINICAL TRIAL; COMPARATIVE STUDY; DISEASE FREE SURVIVAL; DOSE RESPONSE; DRUG ADMINISTRATION; FOLLOW UP; KAPLAN MEIER METHOD; LIVER TUMOR; MIDDLE AGED; MORTALITY; ORAL DRUG ADMINISTRATION; PATHOLOGY; PROCEDURES; RADIOTHERAPY DOSAGE; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

ADMINISTRATION, ORAL; ADULT; AGED; ANTINEOPLASTIC AGENTS; BRACHYTHERAPY; CARCINOMA, HEPATOCELLULAR; DISEASE-FREE SURVIVAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEMALE; FOLLOW-UP STUDIES; HUMANS; KAPLAN-MEIER ESTIMATE; LIVER NEOPLASMS; MALE; MICROSPHERES; MIDDLE AGED; NEOPLASM INVASIVENESS; NEOPLASM STAGING; NIACINAMIDE; PHENYLUREA COMPOUNDS; RADIOTHERAPY DOSAGE; SURVIVAL ANALYSIS; TREATMENT OUTCOME; YTTRIUM RADIOISOTOPES;

EID: 85032178958     PISSN: 14702045     EISSN: 14745488     Source Type: Journal    
DOI: 10.1016/S1470-2045(17)30683-6     Document Type: Article

References (28)

1. Torre, LA, Bray, F, Siegel, RL, Ferlay, J, Lortet-Tieulent, J, Jemal, A, Global cancer statistics, 2012. CA Cancer J Clin 65 (2015), 87–108.
2. Sartorius, K, Sartorius, B, Aldous, C, Govender, PS, Madiba, TE, Global and country underestimation of hepatocellular carcinoma (HCC) in 2012 and its implications. Cancer Epidemiol 39 (2015), 284–290.
3. Abou-Alfa, GK, Schwartz, L, Ricci, S, et al. Phase II study of sorafenib in patients with advanced hepatocellular carcinoma. J Clin Oncol 24 (2006), 4293–4300.
4. Cheng, AL, Kang, YK, Chen, Z, et al. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol 10 (2009), 25–34.
5. Llovet, JM, Ricci, S, Mazzaferro, V, et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 359 (2008), 378–390.
6. Pinter, M, Sieghart, W, Graziadei, I, et al. Sorafenib in unresectable hepatocellular carcinoma from mild to advanced stage liver cirrhosis. Oncologist 14 (2009), 70–76.
7. Llovet, JM, Real, MI, Montana, X, et al. Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial. Lancet 359 (2002), 1734–1739.
8. Lo, CM, Ngan, H, Tso, WK, et al. Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma. Hepatology 35 (2002), 1164–1171.
9. Llovet, JM, Bruix, J, Systematic review of randomized trials for unresectable hepatocellular carcinoma: chemoembolization improves survival. Hepatology 37 (2003), 429–442.
10. Camma, C, Schepis, F, Orlando, A, et al. Transarterial chemoembolization for unresectable hepatocellular carcinoma: meta-analysis of randomized controlled trials. Radiology 224 (2002), 47–54.
11. Golfieri, R, Renzulli, M, Mosconi, C, et al. Hepatocellular carcinoma responding to superselective transarterial chemoembolization: an issue of nodule dimension?. J Vasc Interv Radiol 24 (2013), 509–517.
12. D'Avola, D, Lnarrairaegui, M, Bilbao, JI, et al. A retrospective comparative analysis of the effect of Y90-radioembolization on the survival of patients with unresectable hepatocellular carcinoma. Hepato-gastroenterology 56 (2009), 1683–1688.
13. Sangro, B, Carpanese, L, Cianni, R, et al. Survival after yttrium-90 resin microsphere radioembolization of hepatocellular carcinoma across Barcelona clinic liver cancer stages: a European evaluation. Hepatology 54 (2011), 868–878.
14. Salem, R, Lewandowski, RJ, Mulcahy, MF, et al. Radioembolization for hepatocellular carcinoma using yttrium-90 microspheres: a comprehensive report of long-term outcomes. Gastroenterology 138 (2010), 52–64.
15. Abdel-Rahman, OM, Elsayed, Z, Yttrium-90 microsphere radioembolisation for unresectable hepatocellular carcinoma. Cochrane Database Syst Rev, 2, 2016 CD011313.
16. Vilgrain, V, Abdel-Rehim, M, Sibert, A, et al. Radioembolisation with yttrium-90 microspheres versus sorafenib for treatment of advanced hepatocellular carcinoma (SARAH): study protocol for a randomised controlled trial. Trials, 15, 2014, 474.
17. Forner, A, Reig, ME, de Lope, CR, Bruix, J, Current strategy for staging and treatment: the BCLC update and future prospects. Semin Liver Dis 30 (2010), 61–74.
18. Bruix, J, Sherman, M, Management of hepatocellular carcinoma. Hepatology 42 (2005), 1208–1236.
19. Lau, WY, Kennedy, AS, Kim, YH, et al. Patient selection and activity planning guide for selective internal radiotherapy with yttrium-90 resin microspheres. Int J Radiat Oncol Biol Phys 82 (2012), 401–407.
20. Aaronson, NK, Ahmedzai, S, Bergman, B, et al. The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst 85 (1993), 365–376.
21. Gray, RJ, A class of K-Sample tests for comparing the cumulative incidence of a competing risk. Ann Stat 16 (1988), 1141–1154.
22. Fine, JP, Gray, RJ, A proportional hazards model for the subdistribution of a competing risk. J Am Stat Assoc 94 (1999), 496–509.
23. Uchino, K, Tateishi, R, Shiina, S, et al. Hepatocellular carcinoma with extrahepatic metastasis: clinical features and prognostic factors. Cancer 117 (2011), 4475–4483.
24. Bruix, J, Raoul, JL, Sherman, M, et al. Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma: subanalyses of a phase III trial. J Hepatol 57 (2012), 821–829.
25. Murthy, R, Nunez, R, Szklaruk, J, et al. Yttrium-90 microsphere therapy for hepatic malignancy: devices, indications, technical considerations, and potential complications. Radiographics 25:suppl 1 (2005), S41–S55.
26. Atassi, B, Bangash, AK, Bahrani, A, et al. Multimodality imaging following 90Y radioembolization: a comprehensive review and pictorial essay. Radiographics 28 (2008), 81–99.
27. Shomura, M, Kagawa, T, Okabe, H, et al. Longitudinal alterations in health-related quality of life and its impact on the clinical course of patients with advanced hepatocellular carcinoma receiving sorafenib treatment. BMC Cancer, 16, 2016, 878.
28. Heffernan, N, Cella, D, Webster, K, et al. Measuring health-related quality of life in patients with hepatobiliary cancers: the functional assessment of cancer therapy-hepatobiliary questionnaire. J Clin Oncol 20 (2002), 2229–2239.